argenx SE (STU:1AEA) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 13, 2025)

View and export this data going back to 2019. Start your Free Trial

What is argenx SE Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

argenx SE's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of argenx SE's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, argenx SE's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where argenx SE's Margin of Safety % (DCF Dividends Based) falls into.

Save Embed

;

Save Embed

;

argenx SE Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of argenx SE's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (STU:1AEA) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines